Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER)

Purpose The Western Cape Pregnancy Exposure Registry (PER) was established at two public sector healthcare sentinel sites in the Western Cape province, South Africa, to provide ongoing surveillance of drug exposures in pregnancy and associations with pregnancy outcomes. Participants Established in 2016, all women attending their first antenatal visit at primary care obstetric facilities were enrolled and followed to pregnancy outcome regardless of the site (ie, primary, secondary, tertiary facility). Routine operational obstetric and medical data are digitised from the clinical stationery at the healthcare facilities. Data collection has been integrated into existing services and information platforms and supports routine operations. The PER is situated within the Provincial Health Data Centre, an information exchange that harmonises and consolidates all health-related electronic data in the province. Data are contributed via linkage across a unique identifier. This relationship limits the missing data in the PER, allows validation and avoids misclassification in the population-level data set. Findings to date Approximately 5000 and 3500 pregnant women enter the data set annually at the urban and rural sites, respectively. As of August 2021, >30 000 pregnancies have been recorded and outcomes have been determined for 93%. Analysis of key obstetric and neonatal health indicators derived from the PER are consistent with the aggregate data in the District Health Information System. Future plans This represents significant infrastructure, able to address clinical and epidemiological concerns in a low/middle-income setting.

[1]  L. Myer,et al.  Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment , 2022, BMC Pregnancy and Childbirth.

[2]  D. Edwards,et al.  Use of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent , 2021, Drug Safety.

[3]  O. Khaliq,et al.  An imperative to offer pregnant and lactating women access to the COVID-19 vaccination roll-out programme. , 2021, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[4]  L. Holmes,et al.  Limited surface examination to evaluate potential teratogens in a resource‐limited setting , 2021, Birth defects research.

[5]  S. Madhi,et al.  Maternal and neonatal data collection systems in low- and middle-income countries for maternal vaccines active safety surveillance systems: A scoping review , 2021, BMC Pregnancy and Childbirth.

[6]  D. Bianchi,et al.  Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines. , 2021, JAMA.

[7]  G. Swamy,et al.  Coronavirus disease 2019 vaccines in pregnancy , 2020, American journal of obstetrics & gynecology MFM.

[8]  A. Boulle,et al.  Understanding and Responding to Prescribing Patterns of Sodium Valproate-Containing Medicines in Pregnant Women and Women of Childbearing Age in Western Cape, South Africa , 2020, Drug Safety.

[9]  L. Myer,et al.  Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[10]  N. Tiffin,et al.  Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa , 2019, International journal of population data science.

[11]  G. Montepiedra,et al.  Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. , 2019, The New England journal of medicine.

[12]  M. Hughes,et al.  Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons , 2019, PLoS medicine.

[13]  S. Lockman,et al.  Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. , 2019, The New England journal of medicine.

[14]  H. Rees,et al.  Why South Africa urgently needs to support the development of pregnancy exposure registries. , 2019, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[15]  L. Myer,et al.  Methods of gestational age assessment influence the observed association between antiretroviral therapy exposure, preterm delivery, and small-for-gestational age infants: a prospective study in Cape Town, South Africa. , 2018, Annals of epidemiology.

[16]  A. Moosavi,et al.  Prevalence and Reasons of Self-Medication in Pregnant Women: A Systematic Review and Meta-Analysis , 2018, International journal of community based nursing and midwifery.

[17]  R. Shapiro,et al.  Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.

[18]  A. Boulle,et al.  Assessing the value of Western Cape Provincial Government health administrative data and electronic pharmacy records in ascertaining medicine use during pregnancy , 2018, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[19]  S. Andrade,et al.  Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy , 2017, Current Epidemiology Reports.

[20]  Christian Hampp,et al.  A systematic review of pregnancy exposure registries: examination of protocol‐specified pregnancy outcomes, target sample size, and comparator selection , 2017, Pharmacoepidemiology and drug safety.

[21]  S. Kochhar,et al.  Global alignment of immunization safety assessment in pregnancy - The GAIA project. , 2016, Vaccine.

[22]  Wendy Watson,et al.  Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data , 2016, Vaccine.

[23]  C. Aldous,et al.  South African congenital disorders data, 2006 - 2014. , 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[24]  L. Geerts,et al.  A comparison of pregnancy dating methods commonly used in South Africa: a prospective study. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[25]  M. Petzold,et al.  Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings , 2012, BMC Pregnancy and Childbirth.

[26]  A. Gilbert,et al.  Investigating outcomes associated with medication use during pregnancy: a review of methodological challenges and observational study designs. , 2012, Reproductive toxicology.

[27]  Devon L. Greyson,et al.  Prescription drug use during pregnancy in developed countries: a systematic review , 2011, Pharmacoepidemiology and drug safety.

[28]  Candy Day,et al.  Health and related indicators , 2007 .

[29]  D. Wyszynski,et al.  North American Antiepileptic Drug Pregnancy Registry , 2004, Epilepsia.

[30]  A. Scheuerle,et al.  Clinical review procedures for the Antiretroviral Pregnancy Registry , 2004, Pharmacoepidemiology and drug safety.

[31]  Doris Ma Fat,et al.  WHO Library Cataloguing-in-Publication Data , 2001 .